



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Anti-BCR-ABL [7c6] Standard Size Ab00817-10.3

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors. Developed in partnership with Ximbio ([www.ximbio.com](http://www.ximbio.com)).

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques.

**Isotype and Format:** Human IgG1, Fc Silent™, Kappa

**Clone Number:** 7c6

**Alternative Name(s) of Target:** BCR/ABL; Breakpoint cluster region protein-tyrosine protein kinase ABL1 fusion protein

**UniProt Accession Number of Target Protein:**

**Published Application(s):** IP, WB, IF, IHC

**Published Species Reactivity:** Human

**Immunogen:** Murine antibodies were produced by immunising BALB/c mice with residues 686-696 (SSINEEITPRRQS) of human BCR fused to thyroglobulin. Hybridomas were generated by fusion of immunised cells with the myeloma cell line P3X63Ag8 via established methods.

**Specificity:** This antibody is specific for the SSINEEITPRRQS epitope of BCR (residues 686-696), and as such is able to recognise full-length BCR and the p210 form of the BCR-ABL fusion protein. p210 BCR-ABL is a cytogenetic marker of chronic myelogenous leukaemia, resulting from gross chromosomal translocation resulting in the 'Philadelphia chromosome'. The fusion protein is a constitutively active tyrosine kinase, causing deregulated downstream signalling and increasing likelihood of oncogenic transformation.

**Application Notes:** It has been shown by Western blot that 7c6 binds wildtype, full-length BCR and the p210 BCR-ABL fusion protein.

**Antibody First Published in:** Dhut et al. Identification of two normal bcr gene products in the cytoplasm. *Oncogene*. 1988 Nov;3(5):561-6 [PMID:3078961](https://pubmed.ncbi.nlm.nih.gov/3078961/)

**Note on publication:** Describes the production of 7c6 using a synthetic BCR peptide (corresponding to residues 686-696) and the subsequent use of the antibody in detecting normal BCR and various BCR-ABL fusion gene products.

## Product Form

**Size:** 200 µg Purified antibody.

**Purification:** Protein A affinity purified

**Supplied In:** PBS with 0.02% Proclin 300.

**Storage Recommendation:** Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

**Concentration:** 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.